Midatech Pharma

Midatech is a world leader in the design, synthesis and manufacture of biocompatible gold nanoparticles (GNPs) with a core focus on therapeutics for diabetes and cancer.
Midatech has a strong pipeline of product candidates in clinical and pre-clinical development for the treatment of diabetes and various cancers. In 2012, Midatech established MidaSol Therapeutics LP, a strategic joint venture with MonoSol Rx LLC to focus on the development and commercialization, via partnering or licensing, of products primarily for the treatment of diabetes. MidaSol’s lead product, Midaform™ Insulin PharmFilm, is a unique product for the oral delivery of insulin in diabetic patients and will enter Phase II clinical studies in 2014. These technologies are also being evaluated in the diabetes area by a major US pharmaceutical company.
Midatech’s unique GNP technology enables the administration and targeted delivery of therapeutic compounds to specific cells and tissues. Multiple drug molecules can be attached to one of its GNPs allowing multivalent drug or multi-drug delivery. The size of the GNPs potentially also enables drug delivery via a variety of different routes of administration, such as oral, parental, transdermal, mucosal, intradermal, transbuccal, sublingual or intranasal/inhalation.
Midatech has exclusive world-wide IP for the technology covering design, manufacture and application of nanoparticles in therapeutic and diagnostic pharmaceutical areas as well as in other industries.
In 2014, Midatech Pharma acquired Q Chip, now Midatech Pharma Wales to support novel delivery platforms and product developments in cancer, diabetes and ophthalmology. Q Chip has developed a complementary technology and products that allow sustained release of substances over extended periods of time and will provide a platform to incorporate Midatech's gold nanoparticle (GNP) compounds for sustained and extended release.

Type
Public
Founded
2000
Employees
74 (est)

Key People at Midatech Pharma

Tom Coulter

Tom Coulter

Head of Chemistry
David Webb

David Webb

VP Manufacturing
Nick Robbins-Cherry

Nick Robbins-Cherry

Chief Financial Officer
Emma Matthews

Emma Matthews

Executive PA and HR Manager
Bob Wickoren

Bob Wickoren

Oncology Supportive Care Specialist
Daniel Palmer

Daniel Palmer

Chief Scientific Officer

Midatech Pharma Locations

Milton, GB

Midatech Pharma Metrics

Midatech Pharma Summary

Founding Date

2000

Midatech Pharma Financials

FY, 2013FY, 2014FY, 2015

Revenue

£147 K£157 K£1.38 M

Revenue growth, %

6.8%775.8%

Cost of sales

£70 K

Gross profit

£1.31 M

Gross profit Margin, %

94.9%

Operating expense total

£14.2 M

Midatech Pharma News

Midatech Pharma Company Life

You may also be interested in